相关实验视频
Updated: Jul 16, 2025

14:49
Conducting Respiratory Oscillometry in an Outpatient Setting
Published on: April 8, 2022
7.2K
患者报告,观察员报告和欧洲药物署2013-2018年资格程序中的绩效结果
Marcio Silva1, Jane Moseley2, Thorsten Vetter2
1Exigo Consultores, Lisbon, Portugal.
British journal of clinical pharmacology
|September 12, 2023
概括
欧洲药物署 (EMA) 对超过三分之一的合格计划提供了建设性的反,这些项目涉及患者报告的结果 (PRO),观察员报告的结果 (ObsRO) 和绩效结果 (PerfOs). 鼓励申请人使用这些程序来创建新的结果工具.
科学领域:
- 监管科学 监管科学
- 临床试验方法论 临床试验方法论
- 药物开发 药物开发
背景情况:
- 欧洲药品管理局 (EMA) 为新型结果评估工具提供了资格程序.
- 患者报告的结果 (PROs),观察者报告的结果 (ObsROs) 和性能结果 (PerfOs) 在药物提交中越来越重要.
- 对于开发人员来说,了解这些程序的特点和结果至关重要.
研究的目的:
- 分析申请人的特点,工具,结果和来自EMA资格程序的监管响应.
- 确定从2013年至2018年期间完成的资格认证程序中获得的一般教训.
- 提供对新型成果措施的监管审查的见解.
主要方法:
- 进行了对监管结果的描述性分析和定性审查.
- 数据是从2013年1月至2018年12月期间完成的EMA资格程序中收集的.
- 这项研究侧重于PRO,ObsRO和PerfOs的程序.
主要成果:
- 审查了PRO的17个资格计划,ObsRO的6个和Perfo的11个.
- 胃肠病学和神经病学是最常见的治疗领域.
- 监管机构对申请人的方法表示了高度的部分同意 (超过70%),并为许多工具发布了支持信和资格意见.
- 确定的主要问题包括人口特征,检测变化的能力,干预试验中的验证,定和最小重要的差异.
结论:
- 欧洲药品监管机构提供了建设性的反和支持新型结果工具.
- 超过三分之一的资格计划产生了支持进一步发展的成果.
- 鼓励开发新型PRO,ObsRO和PerfO工具的申请人利用EMA资格程序获得早期反.
相关概念视频
Pharmacovigilance
884
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
884
Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
Preclinical Development: Overview
4.5K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.5K
Drug Regulation
1.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
Clinical Trials
6.8K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.8K
Drug Control Governance: Regulatory Bodies and Their Impact
183
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
183

